Keros director sells 2,625 shares under 10b5-1 plan

Keros Therapeutics director Julius Knowles reported an open-market sale of 2,625 shares of Common Stock at a weighted average price of $10.73 per share.

Rhea-AI Filing Summary

Keros Therapeutics director Julius Knowles reported an open-market sale of 2,625 shares of Common Stock at a weighted average price of $10.73 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.

Following the sale, Knowles holds 10,958 shares directly. In addition, 102,233 shares are held indirectly through Partners Innovation Fund, LLC and 150,047 shares are held indirectly through Partners Innovation Fund II, L.P., where entities associated with him may share voting and investment power.

Insider Trade Summary 10b5-1

Net Seller: 2,625 shares

Net Sell 3 txns

Insider Knowles Julius

Role Director

Sold 2,625 shs ($28K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,625	$10.73	$28K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 10,958 shares (Direct); Common Stock — 252,280 shares (Indirect, See footnote)

Footnotes (4)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
4. F4. The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

Key Figures

Shares sold: 2,625 shares Weighted average sale price: $10.73 per share Price range of sales: $10.61 to $10.89 +4 more

7 metrics

Shares sold 2,625 shares Open-market sale of Common Stock

Weighted average sale price $10.73 per share Common Stock sale on June 4, 2026

Price range of sales $10.61 to $10.89 Multiple transactions within this range

Direct holdings after sale 10,958 shares Common Stock held directly by Julius Knowles

Indirect holdings via PIF I 102,233 shares Held by Partners Innovation Fund, LLC

Indirect holdings via PIF II 150,047 shares Held by Partners Innovation Fund II, L.P.

Rule 10b5-1 plan adoption date December 5, 2025 Plan governing the June 4, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, voting and investment power, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

voting and investment power financial

"may be deemed to share voting and investment power with respect to the shares held by PIF I."

ultimate general partner financial

"Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) disclose for Julius Knowles?

Keros Therapeutics disclosed that director Julius Knowles sold 2,625 shares of Common Stock. The sale was an open-market transaction at a weighted average price of $10.73 per share and was executed under a pre-established Rule 10b5-1 trading plan.

At what price did Julius Knowles sell KROS shares in this Form 4 filing?

Julius Knowles sold 2,625 Keros Therapeutics Common Stock shares at a weighted average price of $10.73. The shares were sold in multiple trades, with individual prices ranging from $10.61 to $10.89 per share, as detailed in the transaction footnotes.

How many Keros Therapeutics shares does Julius Knowles hold after this transaction?

After the reported sale, Julius Knowles holds 10,958 Keros Therapeutics shares directly. He also has indirect holdings of 102,233 shares through Partners Innovation Fund, LLC and 150,047 shares through Partners Innovation Fund II, L.P., where entities associated with him may share voting and investment power.

Was the KROS insider sale by Julius Knowles made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Julius Knowles on December 5, 2025. Such plans pre-schedule trades, indicating the timing of this sale was determined in advance rather than decided opportunistically.

Who holds the indirect Keros Therapeutics (KROS) shares associated with Julius Knowles?

Indirect Keros Therapeutics holdings are reported as 102,233 shares held by Partners Innovation Fund, LLC and 150,047 shares held by Partners Innovation Fund II, L.P. Entities Partners GP I and Partners GP II are ultimate general partners, and Knowles may be deemed to share voting and investment power.

What does the Form 4 say about the pricing of Julius Knowles’ KROS share sale?

The Form 4 notes the $10.73 price is a weighted average across multiple trades. Individual transactions occurred between $10.61 and $10.89 per share, and further detail on exact share counts at each price is available upon request as stated in the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knowles Julius

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		2,625	D	$10.73(2)	10,958	D
Common Stock								150,047	I	See footnote(3)
Common Stock								102,233	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

4. The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

	/s/ Keith Regnante, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)